Cooper Companies (NASDAQ:COO) Upgraded at StockNews.com

StockNews.com upgraded shares of Cooper Companies (NASDAQ:COO) from a hold rating to a buy rating in a report issued on Thursday.

A number of other brokerages have also commented on COO. Morgan Stanley lifted their price objective on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 10th. Wells Fargo & Company boosted their price target on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Robert W. Baird raised their price objective on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cooper Companies presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

Cooper Companies Trading Down 0.2 %

COO opened at $99.63 on Thursday. Cooper Companies has a 1-year low of $82.21 and a 1-year high of $112.38. The stock has a market capitalization of $19.84 billion, a PE ratio of 55.50, a PEG ratio of 2.15 and a beta of 0.99. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $106.83 and a two-hundred day moving average price of $98.06.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.05. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. Cooper Companies’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.84 EPS. As a group, equities analysts anticipate that Cooper Companies will post 3.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the transaction, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This represents a 41.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Agostino Ricupati sold 1,601 shares of Cooper Companies stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. This represents a 24.94 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 256,373 shares of company stock valued at $27,637,427. Company insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Cooper Companies

A number of large investors have recently bought and sold shares of COO. Geode Capital Management LLC boosted its stake in shares of Cooper Companies by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 4,796,556 shares of the medical device company’s stock worth $527,476,000 after buying an additional 48,559 shares during the last quarter. Barclays PLC boosted its position in Cooper Companies by 0.7% during the third quarter. Barclays PLC now owns 462,947 shares of the medical device company’s stock valued at $51,082,000 after purchasing an additional 3,070 shares during the last quarter. Nomura Asset Management Co. Ltd. grew its stake in Cooper Companies by 8.1% in the third quarter. Nomura Asset Management Co. Ltd. now owns 58,703 shares of the medical device company’s stock valued at $6,477,000 after purchasing an additional 4,408 shares in the last quarter. MML Investors Services LLC increased its position in shares of Cooper Companies by 1.6% during the 3rd quarter. MML Investors Services LLC now owns 17,787 shares of the medical device company’s stock worth $1,963,000 after purchasing an additional 280 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in shares of Cooper Companies during the 3rd quarter worth approximately $501,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.